ArticleJournal of the Chinese Medical Association : JCMA2025
The influences of antihistamine on liver fibrosis, vasoresponsiveness, and portosystemic shunting in bile duct-ligated cirrhotic rats.
Article in Journal of the Chinese Medical Association : JCMA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Repurposing antihistamines beyond allergy control: Emerging therapeutic potentials in liver cirrhosis.Journal of the Chinese Medical Association : JCMA · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver cirrhosis with portal hypertension is a sequela of chronic hepatitis, characterized by liver fibrosis, poor portosystemic collateral vasoresponsiveness, increased mesenteric angiogenesis, and collateral formation. Antihistamines are frequently used to control pruritus in cirrhotic patients, and it has also been shown to reverse histamine-induced inflammation, fibrogenesis, angiogenesis, and vasodilatation. However, the relevant impacts on cirrhosis are not clear.
methodsLiver cirrhosis was induced in rats with common bile duct ligation (BDL). Sham rats were surgical controls. Levocetirizine (0.5 mg/kg/day, oral gavage) or vehicle was administered from the 1st day after operations and experiments were performed on the 29th day to survey: (a) Systemic and splanchnic hemodynamic parameters; (b) serum liver and renal biochemistry parameters; (c) protein expressions of liver fibrogenesis factors; (d) portosystemic collateral vasoresponsiveness to vasopressin; (e) portosystemic shunting degree; and (f) mesenteric angiogenesis.
resultsCompared with the vehicle, levocetirizine decreased portal pressure, superior mesenteric artery flow, portal vein (PV) flow, and elevated PV resistance in BDL rats. Levocetirizine significantly down-regulated the hepatic TGF-β, p-Smad2, MMP-2, and TIMP-1 protein expressions in BDL rats. Levocetirizine did not affect the collateral vasoresponsiveness to vasopressin but tended to reduce the severity of portosystemic shunting and mesenteric angiogenesis.
conclusionLevocetirizine ameliorated liver fibrosis, portal hypertension, and splanchnic hyperdynamic circulation in cirrhotic rats, possibly through the downregulation of hepatic fibrogenesis factors. Antihistamines may be a therapeutic option to control portal hypertension. However, further investigations are required to clarify its clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.